Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06117774 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
A Phase 3 study of Small-cell Lung Cancer and Limited Stage Small Cell Lung Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06117774: Recruiting Phase 3 study of Small-cell Lung Cancer and Limited Stage Small Cell Lung Cancer, sponsored by Amgen.
NCT06117774 is a Phase 3 study of Small-cell Lung Cancer and Limited Stage Small Cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 400 participants, above the 227-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06117774, a Phase 3 study of Small-cell Lung Cancer and Limited Stage Small Cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tarlatamab
Study Locations (20)
New York
- New York University Grossman School of Medicine and New York University Langone Hospitals - New York
- Perlmutter Cancer Center at New York University Langone Hospital - Long Island - New York
- Montefiore Einstein Center for Cancer Care - The Bronx
California
- Valkyrie Clinical Trials - Los Angeles
- University of California Los Angeles - Santa Monica
Pennsylvania
- Lehigh Valley Health Network - Allentown
- Spokenword Clinical Trials - Easton
Texas
- Renovatio Clinical - The Woodlands
- US Oncology Research Investigational Products Center - The Woodlands
Virginia
- University of Virginia Health System - Charlottesville
- Virginia Cancer Specialists, PC - Fairfax
Buenos Aires
- Fundacion Respirar - Ciudad Autonoma de Buenos Aires
- Hospital Italiano de La Plata - La Plata
Connecticut
- Yale New Haven Hospital - New Haven
Florida
- Boca Raton Clinical Research Global South Florida - Plantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2030-05-29 |
| Phase | Phase 3 |
What NCT06117774 shows while recruiting
NCT06117774 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 227-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (76% higher).
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06117774 names 20 study sites across 13 states, led by New York, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06117774 about?
NCT06117774 is a clinical study titled "Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)". The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).
What is the current status of trial NCT06117774?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-02-20. Estimated completion is 2030-05-29.
What conditions does trial NCT06117774 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Limited Stage Small Cell Lung Cancer.
What interventions are being tested in trial NCT06117774?
The interventions under investigation include: Placebo (DRUG), Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT06117774?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06117774 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06117774's enrollment target sits among peer trials
400 16th of 79 higher than 64 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI